The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Open accessAbstract
Importance: Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-related mortality in NASH. There are no known efficacious treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have been completed. Objective: To synthesize the evidence about the association of thiazolidinedione therapy with advanced liver fibrosis in NASH. Data Sources: MEDLINE, Ovid MEDLINE In-Process, Cochrane Library, EMBASE, clinicaltrials.gov, PubMed, and Scopus databases (without language restrictions), as well as other registries and scientific meeting presentations, from database inception through August 15, 2016. Study Selection: Randomized clinical trials evaluating the effect of thiazolidinedione therapy on histologic features of the liver in biopsy-proven NASH. Data Extraction and Synthesis: Two investigators extracted study data independently and in duplicate and rated the risk of bias using the Cochrane Risk of Bias Tool. Main Outcomes and Measures: The primary outcome was a dichotomous improvement in advanced fibrosis on liver biopsy, defined as an improvement in fibrosis stage from F3-F4 to F0-F2. Secondary outcomes were at least a 1-point improvement in fibrosis of any stage and NASH resolution. This meta-analysis also evaluated adverse effects of thiazolidinedione therapy, including weight gain, lower limb edema, congestive heart failure, bone fractures, cancer, and anemia. With the use of random-effects models, dichotomous variables are presented as odds ratios (ORs) with 95% CIs, and continuous variables are presented as weighted mean differences with 95% CIs. Results: This study analyzed 8 RCTs (5 evaluating pioglitazone use and 3 evaluating rosiglitazone maleate use) enrolling 516 patients with biopsy-proven NASH for a duration of 6 to 24 months. Among all studies combined, thiazolidinedione therapy was associated with improved advanced fibrosis (OR, 3.15; 95% CI, 1.25-7.93; P = .01; I2 = 0%), fibrosis of any stage (OR, 1.66; 95% CI, 1.12-2.47; P = .01; I2 = 0%), and NASH resolution (OR, 3.22; 95% CI, 2.17-4.79; P < .001; I2 = 0%). Analyses restricted to RCTs enrolling patients without diabetes yielded similar results for improvement in advanced fibrosis (OR, 2.95; 95% CI, 1.04-10.90; P = .02; I2 = 0%), improvement in fibrosis of any stage (OR, 1.76; 95% CI, 1.02-3.03; P = .02; I2 = 0%), and NASH resolution (OR, 3.40; 95% CI, 1.95-5.93; P < .001; I2 = 0%). All effects were accounted for by pioglitazone use. Weight gain and lower limb edema occurred more frequently with thiazolidinedione therapy (initial body weight +2.70%; 95% CI, 1.96%-4.34%; P = .001). The small sample size of included RCTs prevented evaluation of more serious adverse effects of thiazolidinedione therapy. Conclusions and Relevance: Pioglitazone use improves advanced fibrosis in NASH, even in patients without diabetes. Whether this finding translates to improvement in risk for clinical outcomes requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [293]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In MASH, treatment with pioglitazone, the most prescribed PPARγ agonistic drug over the last decades, was repeatedly associated with improvements in liver histology, despite a net weight gain of 2-4 % of body weight (Table 1) [176,177].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [176]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PPARα agonist action on lipid metabolism is driven by stimulation of hepatic fatty acid transport, lipolysis and peroxisomal as well as mitochondrial β-oxidation [172].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [172]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Wong, R. J., Aguilar, M. E. F., Cheung, R. C., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,861
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Cited by
Sorted by citations
Items 301–400 of 450
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Long-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study
Pereira, I. V. A., de Oliveira, A. B. S., Zitelli, P. M., Barbieri, L. A., Cardoso, A. C., Monteiro, M. J. D. S. D., de Oliveira, J. S., Stefano, J. T., Altikes, R. G., Reis, A. L. G., et al. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100737 · Cited by 8
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 9
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32479 · Cited by 8
Dietary factors in nonalcoholic fatty liver disease: impacts on human and animal health - a review
Yeung, A. W. K., Ksepka, N., Matin, M., Wang, D., Souto, E. B., Stoyanov, J. V., Echeverría, J., Tewari, D., Horbańczuk, J. O., Lucarini, M., et al. (2023) · Animal Science Papers and Reports · doi:10.2478/aspr-2023-0007 · Cited by 8
Albert, S. G., & Wood, E. M. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102232 · Cited by 8
Jeon, K., Kumar, A., Callan, C. L., DeMagistris, M., Macrae, S. M., Nehrke, K. W., & Huxlin, K. R. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.13.36 · Cited by 10
Current treatment for non-alcoholic fatty liver disease
Moctezuma‐Velázquez, C. (2018) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2018.05.014 · Cited by 8
Ren, T., Eslam, M., & Fan, J. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0558 · Cited by 8
Medical care of liver transplant patients
Hoppmann, N. A., & Massoud, O. I. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1797483 · Cited by 8
Lundholm, M. D., Bena, J., Zhou, K., Tsushima, Y., & Kashyap, S. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108405 · Cited by 7
Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100145 · Cited by 7
Cui, H., & Zhang, X. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0595 · Cited by 8
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 9
Editorial: diabetes, obesity and clinical inertia—the recipe for advanced NASH
Leey, J., & Cusi, K. J. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14473 · Cited by 7
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 8
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1
Yin, Y.-H., Sang, L.-X., & Chang, B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i48.6235 · Cited by 6
Chinese medicine formulas for nonalcoholic fatty liver disease: Overview of systematic reviews
Dai, L., Zhou, W., Zhong, L. L. D., Tang, X.-D., & Ji, G. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i1.102 · Cited by 6
Kim, H. J., Jeong, I., Hur, K. Y., Kim, S., Noh, J. H., Chun, S. W., Kang, E. S., Rhee, E., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0183 · Cited by 6
Role of Soluble Adiponectin Receptor 2 in Non-Alcoholic Fatty Liver Disease in Children
Aksoy, G. K., Artan, R., Aksoy, C., Özdem, S., Atalay, A., & Yılmaz, A. (2019) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2019.22.5.470 · Cited by 6
Update on cardiovascular risk in nonalcoholic fatty liver disease
Johnston, M. P., Patel, J., & Byrne, C. D. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000861 · Cited by 6
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 9
Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist
Millán-Rodríguez, C., Castello, C. P., Valderrama, M. D. R. C., & Barón‐Esquivias, G. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.22 · Cited by 5
Fibrosis and diabetes: Chronic hyperglycemia triggers organ-specific fibrotic mechanisms
Basson, R., & Bayat, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816413-6.00007-1 · Cited by 6
Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery
Zhang, X., Li, J., Liu, T., Zhao, M., Liang, B., Chen, H., & Zhang, Z. (2022) · Disease Markers · doi:10.1155/2022/4369329 · Cited by 5
RetractedAsakawa, M., Takagi, N., Hamada, D., Yamasaki, Y., & Katsuta, H. (2023) · Diabetology International · doi:10.1007/s13340-023-00619-z · Cited by 5
Zeng, M., Chen, L., Li, Y., Mi, Y., & Xu, L. (2023) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000085 · Cited by 5
Katakura, Y., Shimoda, M., Ohnishi, M., Kusano, T., Dan, K., Isobe, H., Wamata, R., Iwamoto, Y., Fushimi, Y., Sanada, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.02.011 · Cited by 5
What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease?
Mansour, A., Hekmatdoost, A., & Mirmiran, P. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12751 · Cited by 5
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 4
Bio-fabrication of fibrotic liver microtissues as a scalable and drug-responsive in vitro model
Majidi, F., Choshali, M. A., Izadi, A., Hajari, M. A., Saheli, M., Ziai, S. A., Vosough, M., & Piryaei, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126242 · Cited by 5
RSSDI guidelines for management of type 2 diabetes mellitus in older adults
Jagadeesha, A., Viswanathan, V., Agarwal, S., Maheshwari, A., Virmani, A. K., Nagendra, L., Amarnath, A., Chawla, M. S., Jethwani, P., Parikh, R. M., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01613-8 · Cited by 4
Targeting metabolism in the management of PCOS: Metformin and beyond
Oğuz, S. H., Şendur, S. N., Ünlütürk, U., & Yıldız, B. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00006-7 · Cited by 5
Hu, Y., Lan, Y., Ran, Q., Gan, Q., Tang, S., & Huang, W. (2022) · Processes · doi:10.3390/pr10091735 · Cited by 4
Iwanishi, M., Ito‐Kobayashi, J., Washiyama, M., Kusakabe, T., & Ebihara, K. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0225-17 · Cited by 4
Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
Schwartz, S. L., Lucas, J., DeLegge, M. H., & IQVIA, R. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.112 · Cited by 4
Pioglitazone-Enhanced Brown Fat Whitening Contributes to Weight Gain in Diet-Induced Obese Mice
Yu, P., Wang, W. J., Guo, W., Cheng, L., Wan, Z., Cheng, Y., Shen, Y., & Xu, F. L. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2178-9113 · Cited by 6
Advances in the treatment of hepatogenous diabetes: A review
Deng, Y., Li, K., Li, A., Hu, W., & Hu, W. (2023) · Medicine · doi:10.1097/md.0000000000036068 · Cited by 4
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Wang, X., Zheng, T., Liu, B., Pei, Z., Meng, K., & Ling, C. (2025) · JMIR Formative Research · doi:10.2196/66503 · Cited by 3
Recent advances in the design, development and therapeutic applications of PPARγ agonists
Ghannam, I. A. Y., Abdel‐Mohsen, H. T., & Ali, I. H. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2571022 · Cited by 3
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 3
Pashayee-Khamene, F., Hatami, B., Cheraghpour, M., & Yari, Z. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.09.927 · Cited by 3
Alexopoulos, A., Parish, A., Olsen, M. K., Batch, B. C., Moylan, C. A., & Crowley, M. J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003763 · Cited by 3
Zhou, D., Zhu, W., Liu, H., Zhang, F., Zhou, X., Zhang, X., Zhao, Y., Huang, Y., & Duan, X. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100922 · Cited by 3
ER Stress Response Failure and Steatohepatitis Comorbid with Diabetes
Sasako, T., & Ueki, K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100054 · Cited by 3
Bril, F., Kalavalapalli, S., Lomonaco, R., & Cusi, K. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14936 · Cited by 3
Obesity, Ectopic Fat and Type 2 Diabetes
Verhaegen, A. A., & Gaal, L. F. V. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch10 · Cited by 3
Tran, Q. T., Bui, T. T., Ngo, L. T., Yang, B. R., Baek, I., Nguyen, V. H., Lee, K. A., Yun, H., Chae, J., Lee, S., et al. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70034 · Cited by 3
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
Abushamat, L. A., & Barb, D. (2025) · Hepatology · doi:10.1097/hep.0000000000001511 · Cited by 2
Нисановна, С. А., Goncharov, A. А., Morozov, S. V., Pilipenko, V. I., & Va, I. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.08.203339 · Cited by 2
Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Alexopoulos, A., & Cusi, K. J. (2026) · Diabetes Care · doi:10.2337/dci26-0019 · Cited by 2
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 5
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzı́k, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 3
Surgical Issues in NASH: Bariatric Surgery and Liver Transplantation
Paul, S., & Charlton, M. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0429-3 · Cited by 2
Hu, K., Zhang, H., Shu, M., & Wang, X. (2023) · Cancer Medicine · doi:10.1002/cam4.5912 · Cited by 2
Demidova, T. Y., Скуридина, Д. В., & Pervushina, E. S. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-17 · Cited by 2
Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease
Yang, H., & Park, C. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.2.88 · Cited by 2
Association of insulin resistance and non-alcoholic fatty liver disease
Mishina, E. Е., Mayorov, A. Y., Bogomolov, P., Liusina, E. O., & Bueverov, A. O. (2021) · Diabetes Mellitus · doi:10.14341/dm12234 · Cited by 2
Lee, C. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.01.005 · Cited by 3
Global Trends of Treatment for NAFLD from 2012 to 2021: A Bibliometric and Mapping Analysis
Song, Y., Chen, B., Jiang, L., Zhao, F., & Feng, X. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303230418230925060312 · Cited by 2
McCommis, K. S., Colca, J. R., & Finck, B. N. (2017) · Hepatology · doi:10.1002/hep.29162 · Cited by 2
Letter: metformin treatment and hepatocellular carcinoma risk in non‐alcoholic fatty liver disease
Doğru, T., Kırık, A., & Sönmez, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15462 · Cited by 2
Impacts of Non-alcoholic Fatty Liver Disease on Acute Coronary Syndrome: Evidence and Controversies
Shi, S., Jia, F., Wang, M., Zhou, Y., & Li, J. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01146-7 · Cited by 1
Nawata, H., Ou, L., Zhang, X., Song, Q., Huang, J., Hu, J., Ito, K., Obo, S., Fukushima, T., Iwami, K., et al. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0554 · Cited by 1
Wang, J., Ding, D., Shao, X., Ma, L., Xu, J., Melehani, J. H., Boyette, L. B., Watkins, T. R., Jia, C., Malkov, V. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16443 · Cited by 1
Rogers, G., Landi, S., Purssell, H., Momoh, T., Yates, S., Street, O., Hanley, K. P., Hanley, N. A., Athwal, V. S., & Payne, K. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003480 · Cited by 1
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 1
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 1
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Choi, J., Fulop, D., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0825 · Cited by 2
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 1
A transdisciplinary framework for managing metabolic dysfunction associated steatotic liver disease
Kouser, S., Sharma, S. V., Bhanu, A., Kukkupuni, S. K., & Vishnuprasad, C. N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1767844 · Cited by 2
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Knorr, J. P., Reese, R., Serbantez, M., & Lin, K. P. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag095 · Cited by 1
Xue, L., Wang, X., & Mao, J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1808135 · Cited by 1
吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
MASLD as Complication of Diabetes
Stefan, N. (2026) · Diabetes · doi:10.2337/dbi26-0001 · Cited by 1
Gastaldelli, A., Choi, E., Conde‐Knape, K., Göransson, O., Krook, A., Lehtonen, S. H., Roden, M., Schrauwen, P., Sparks, L. M., & Heni, M. (2026) · Diabetologia · doi:10.1007/s00125-026-06853-9 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Neue arzneitherapeutische Optionen bei nichtalkoholischer Fettlebererkrankung
Stefan, N. (2020) · Der Internist · doi:10.1007/s00108-020-00801-4 · Cited by 1
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root
Aggarwal, P., Singh, T., & Alkhouri, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00533-x · Cited by 1
Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Bagriy, A. E., Zubov, A. D., Khomenko, M. V., Михайличенко, Е. С., Пылаева, Е. А., Khaustova, N. A., & Bryukhovetskaya, E. V. (2021) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-2-14-26 · Cited by 1
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
Garbuzenko, D. V. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-5-16-24 · Cited by 1
NAFLD and type 2 diabetes: A practical guide for the joint management
Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.12.010 · Cited by 1
NAFLD, the hepatic manifestation of the metabolic syndrome
Chaudhury, T., Brodosi, L., Marchesini, G., Mitra, S. K., & Petroni, M. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00055-4 · Cited by 1
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis
Iwaki, M., Yoneda, M., Wada, N., Otani, T., Kobayashi, T., Nogami, A., Saito, S., & Nakajima, A. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2328036 · Cited by 1
Non-alcoholic fatty liver disease and its role in the development of cardiovascular diseases
Владимировна, Д. С., Семикова, Г. В., Викторовна, Ш. З., Cherebillo, I. V., & ХОШАФЯН, Н. М. (2023) · Vrach · doi:10.29296/25877305-2023-11-10 · Cited by 1
Maev, I. V., Osadchuk, M., Osadchuk, M. A., & Mironova, E. D. (2020) · Medical news of the North Caucasus · doi:10.14300/mnnc.2020.15141 · Cited by 1
Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie
Apostolopoulou, M., & Roden, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_20 · Cited by 1
Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.007 · Cited by 1
Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease
Mihai, C., Mihai, B. M., & Prelipcean, C. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_14 · Cited by 1
Musso, G., & Gambino, R. (2017) · Hepatology · doi:10.1002/hep.29164 · Cited by 1
Self-citationDiabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Khaliq, A., Badshah, H., Shah, Y., & Rehman, I. U. (2024) · Research Square · doi:10.21203/rs.3.rs-3982234/v1 · Cited by 1
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
The Role of Pioglitazone in the Management of Nonalcoholic Steatohepatitis
Yee, H. F. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9669
NASH: Fortgeschrittene Leberfibrose bessert sich unter Pioglitazon
Thimme, R. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-111695
Metadata
- Authors
- Musso, G., Cassader, M., Paschetta, E., & Gambino, R.
- Affiliations
- Ospedale Humanitas Gradenigo (IT)
- University of Turin (IT)
- Corresponding author
- Musso, Giovanni
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2017-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 633
- ISSN
- 2168-6106 (ISSN-L)
- PMC
- PMC5470366
- OpenAlex
- W2593506275
- Cited by
- 449
- References
- 31
- Citations by year
- 2026: 37 · 2025: 49 · 2024: 45 · 2023: 69 · 2022: 58 · 2021: 66 · 2020: 39 · 2019: 33 · 2018: 32 · 2017: 18
- FWCI
- 26.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Internal Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- thiazolidinediones, nonalcoholic steatohepatitis, advanced liver fibrosis, pioglitazone, rosiglitazone, NASH resolution, adverse drug reactions, weight gain, congestive heart failure, anemia, drug safety, liver transplantation risk, risk of bias assessment, risk of bias
- MeSH terms
- Pioglitazone, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Treatment Outcome, Disease Progression, Thiazolidinediones, Non-alcoholic Fatty Liver Disease, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
